GWP42003-P

Phase 3Small molecule

Jazz Pharmaceuticals

GWP42003-P is one of 166 small molecule programs targeting Lennox-Gastaut syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

165

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lennox-Gastaut SyndromeActive, not recruiting

Rett SyndromeActive, not recruiting

Autism Spectrum DisorderActive, not recruiting

EpilepsyActive, not recruiting

SchizophreniaActive, not recruiting

Infantile SpasmsActive, not recruiting

Tuberous SclerosisActive, not recruiting

Dravet SyndromeActive, not recruiting

Lennox-Gastaut SyndromePhase 3

Active, not recruiting

Rett SyndromePhase 3

Active, not recruiting

Autism Spectrum DisorderPhase 2

Active, not recruiting

EpilepsyPhase 3

Active, not recruiting

SchizophreniaPhase 2

Active, not recruiting

Infantile SpasmsPhase 3

Active, not recruiting

Tuberous SclerosisPhase 3

Active, not recruiting

Dravet SyndromePhase 2

Active, not recruiting

Competition

Competitive Landscape

583 competitors in Schizophrenia

#DrugCompanyPhaseTrials

GWP42003-P

Jazz Pharmaceuticals

Phase 3

1 2

Celexa

AbbVie

Preclinical

4 3

Ozempic

Novo Nordisk

Preclinical

1 4

Resotran

Takeda

Preclinical

1 5

Inapsine

Alnylam Pharmaceuticals

Preclinical

1 6

Zocor

OOrganon and Co

Preclinical

6 7

Depakote

Ibrance

Lunesta

3 10

Luvox

SSolvay Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lennox-Gastaut syndrome4 trials

A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 3·NCT02224690·171 enrolled

An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes

Completed·GGW Research Ltd·Phase 3·NCT02224573·681 enrolled

Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

Terminated· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 3·NCT04485104·3 enrolled

Show 1 more trial

Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 3·NCT02224560·225 enrolled

Dravet syndrome3 trials

A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 2·NCT02091206·34 enrolled

Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 3·NCT02091375·120 enrolled

GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 3·NCT02224703·199 enrolled

Drug Interactions3 trials

An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 2·NCT02564952·18 enrolled

An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 2·NCT02607904·30 enrolled

A Study of Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 2·NCT02607891·35 enrolled

Infantile Spasms2 trials

Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 3·NCT02953548·9 enrolled

Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 3·NCT02954887·9 enrolled

Tuberous Sclerosis2 trials

An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 3·NCT02544750·199 enrolled

A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 3·NCT02544763·224 enrolled

6 more indications

Rett syndrome2 trials

Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

Terminated· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 3·NCT03848832·29 enrolled

A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

Terminated· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 3·NCT04252586·21 enrolled

Randomized Controlled Trial1 trial

A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 2·NCT02565108·20 enrolled

Schizophrenia1 trial

Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment

Terminated· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 2·NCT04421456·95 enrolled

Autism Spectrum Disorder1 trial

Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 2·NCT04745026·103 enrolled

Epilepsy1 trial

Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures

Terminated· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 3·NCT05288283·3 enrolled

Outcome1 trial

Investigation of Cognitive Outcomes With Cannabidiol Oral Solution

Withdrawn· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 4·NCT04133480

Sources

References

[1]
ClinicalTrials.gov — 21 trial records for GWP42003-P. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GWP42003-P compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GWP42003-P. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jazz Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Jazz Pharmaceuticals

GWP42003-P

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lennox-Gastaut syndrome4 trials

Dravet syndrome3 trials

Drug Interactions3 trials

Infantile Spasms2 trials

Tuberous Sclerosis2 trials

Rett syndrome2 trials

Randomized Controlled Trial1 trial

Schizophrenia1 trial

Autism Spectrum Disorder1 trial

Epilepsy1 trial

Outcome1 trial

References

Drug Info

Quick Facts

Related News